

Influenza A(H1N1)pdm09 egg-derived¹ candidate vaccine viruses for development and production of vaccines for use in the 2026 southern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)²

26 September 2025 (Last updated 05 January 2026)

Candidate vaccine viruses (CVVs) antigenically like A/Missouri/11/2025 (egg-derived) - Accession number (GISAID): EPI_ISL_20066835

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Missouri/11/2025	Wild Type		CDC	CDC
	SAN-046	Classical	Sanofi	Sanofi, USA
	IVR-279	Classical	Seqirus	MHRA pending
A/Switzerland/6849/2025	Wild Type		FCI	
	IVR-278	classical	Seqirus	

Institutes contact details for candidate vaccine virus orders/information:

CDC: cvvrequest@cdc.gov (Subject: CVV request)

MHRA: standards@mhra.gov.uk or enquiries@mhra.gov.uk

Sanofi: raymond.schwartz@sanofi.com

WHO CCs and ERLs: http://www.who.int/influenza/gisrs_laboratory/collaborating_centres

¹ For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

² <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

Reference antigens (freeze dried)

Parent virus	Starting materials		Ref Ag lot number	Unitage (µg HA/ml)	Available from
	Candidate vaccine virus	Egg or cell			
A/Switzerland/6849/2025	IVR-278	Egg	2025/1548*	57	TGA, Australia
			H1-Ag-2513*	50	CBER/FDA, USA
			25/222*	54	MHRA, UK

*New reagents shown in blue

Sheep antisera

Purified HA from		Order lot number	Available from
Parent virus	Egg or cell		
A/Missouri/11/2025-like	Egg	AS467*	TGA, Australia
		25/224*	MHRA, UK
		H1-Ab-2512*	CBER/FDA, USA

*New reagents shown in blue

WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

MHRA: standards@mhra.gov.uk or enquiries@mhra.gov.uk

NIID: flu-vaccine@nih.go.jp

TGA: influenza.reagents@tga.gov.au

For reagents available from **CBER**, email CBERShippingRequests@fda.hhs.gov.

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact gisrs-whohq@who.int